Skip to main content
January 24, 2005

Predictors of cognitive dysfunction in patients with systemic lupus erythematosus

January 25, 2005 issue
64 (2) 297-303


Objective: To evaluate predictors of cognitive dysfunction in patients with systemic lupus erythematosus (SLE).
Methods: The authors evaluated 123 patients enrolled in the San Antonio Lupus Study of Neuropsychiatric Disease (SALUD) who had completed at least 3 years of follow-up. Study visits occurred every 4 months and included a standard medical history, physical examination, and cognitive testing. Blood was obtained at each study visit for autoantibody testing.
Results: There were 116 (94.3%) women and 7 (5.7%) men (mean age = 41.5 [±12.0] years). Patients had the following vascular risk factors: hypercholesterolemia (17.1%), diabetes (21.1%), and hypertension (48.0%). Consistent medication use included aspirin (21.1%), prednisone (65.0%), nonsteroidal anti-inflammatories (42.3%), and hydroxychloroquine (58.5%). The numbers of patients with consistently positive autoantibody levels were as follows: antiphospholipid, 54%; anti-beta-2-glycoprotein 1, 73%; and anti-ribosomal P, 17%. Factors significantly associated with declining cognitive function were consistently positive antiphospholipid antibodies, consistent prednisone use, diabetes, higher depression scores, and less education. The association of prednisone and poorer cognitive function was seen primarily in the middle age group and could not be totally explained by SLE-associated disease activity. Consistent aspirin use was associated with improved cognitive function, primarily in the oldest age group, especially if diabetes was also present.
Conclusions: Regular aspirin use is associated with improved cognitive function in older patients with systemic lupus erythematosus (SLE) in conjunction with the presence of other vascular risk factors. Regular prednisone use is associated with decreased cognitive functioning in middle-aged patients with SLE. Although this prednisone effect was independent of measures of SLE-associated disease activity, the authors cannot exclude the possibility that consistent prednisone use is a surrogate for more severe disease.

Get full access to this article

View all available purchase options and get full access to this article.


Uramoto KM, Michet CJ, Thumboo J Jr., et al. Trend in the incidence and mortality of systemic lupus erythematosus, 1950–1992. Arthritis Rheum 1999;42:46–50.
Michet Jr CJ, McKenna CH, Elveback LR, Kaslow RA, Kurland LT. Epidemiology of systemic lupus erythematosus and other connective tissue diseases in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 1985;60:105–113.
American College of Rheumatology (ACR) ad hoc committee on neuropsychiatric lupus. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndrome. Arthritis Rheum 1999;42:599–608.
Brey RL, Holliday SL, Saklad AR, et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002;58:1214–1220.
Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001;57:496–499.
Kozora E, Thompson LL, West SG, Kotzin BL. Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum 1996;39:2035–2045.
Denburg SD, Carbotte RM, Ginsberg JS, Denburg JA. The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus. J Int Neuropsychol Soc 1997;3:377–386.
Glanz BI, Slonim D, Urowitz MB, et al. Pattern of neuropsychologic dysfunction in inactive systemic lupus erythematosus. Neuropsychiatry Neuropsychol Behav Neurol 1997;10:232–238.
Sabbadini MG, Manfredi AA, Bozzolo E, et al. Central nervous system involvement in systemic lupus erythematosus patients without overt neuropsychiatric manifestations. Lupus 1999;8:11–19.
Leritz E, Brandt J, Minor M, Reis-Jensen F, Petri M. “Subcortical” cognitive impairment in patients with systemic lupus erythematosus. J Int Neuropsychol Soc 2000;6:821–825.
Keenan PA, Jacobson MA, Soleymani MA, Mayes MD, Stress ME, Yaldoo DT. The effect on memory of chronic prednisone treatment in patients with systemic disease. Neurology 1996;47:396–1402.
Wolkowitz OM, Reus VI, Weingartner H, et al. Cognitive effects of corticosteroids. Am J Psychiatry 1990;147:1297–1303.
Hanly JG, Cassell K, Fisk JD. Cognitive function in systemic lupus erythematosus: results of a 5-year prospective study. Arthritis Rheum 1997;40:1542–1543.
Menon S, Jameson-Shortall E, Newman SP, Hall-Craggs MR, Chinn R, Isenberg DA. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum 1999;42:735–741.
Hanly JG, Hong C, Smith S, Fisk JD. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum 1999;42:728–734.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–1277.
Bleiberg J, Kane RL, Reeves DL, Barmoe WS, Halpern E. Factor analysis of computerized and traditional tests used in mild brain injury research. Clin Neuropsychol 2000;14:287–294.
Holliday SL, Navarrete MG, Hermosillo-Romo D, et al. Validating a computerized neuropsychological test battery for mixed ethnic lupus patients. Lupus 2003;12:1–7.
Reeves D, Kane R, Winter K. Automated neuropsychological assessment metrics (ANAM v3.11a/96) user’s manual: clinical and neurotoxicology subset (report no. NCRF-SR-96–01). San Diego: National Cognitive Foundation, 1996.
Addington D, Addington J, Schissel B. A depression scale for schizophrenics. Schizophr Res 1990;3:247–251.
Hamilton MA. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. Rheumatology 1992;35:630–640.
Gladman DD, Ginzler E, Goldsmith C, et al. The development and initial validation of the systemic lupus international collaborative clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363–369.
Collie A, Shafiq-Antonacci R, Maruff P, Tyler P, Currie J. Norms and the effects of demographic variables on a neuropsychological battery for use in healthy aging Australian populations. Aust NZ J Psychiatry 1999;33:568–575.
Hughes DL, Bryan J. Adult age differences in strategy use during verbal fluency performance. J Clin Exp Neuropsychol 2002;24:642–544.
Jenkins L, Myerson J, Joerding JA, Hale S. Converging evidence that visuospatial cognition is more age-sensitive than verbal cognition. Pyschol Aging 2000;15:157–175.
Loonstra AS, Tarlow AR, Sellers AH. COWAT metanorms across age, education, and gender. Appl Neuropsychol 2001;8:161–166.
Lyketsos CG, Chen LS, Anthony JC. Cognitive decline in adulthood: an 11.5-year follow-up of the Baltimore Epidemiologic Catchment Area Study. Am J Psychiatry 1999;156:58–65.
Nilsson LG. Memory function in normal aging. Acta Neurol Scand Suppl 1993;179:7–13.
Norman MA, Evans JD, Miller WS, Heaton RK. Demographically corrected norms for the California Verbal Learning Test. J Clin Exp Neuropsychol 2000;22:80–94.
Fortin PR, Abrahamowicz M, Clarke AE, et al. Do lupus disease activity measures detect clinically important change? J Rheumatol 2000;27:1421–1428.
Fortin PR, Abrahamowicz M, Neville C, et al. Impact of disease activity and cumulative damage on the health of lupus patients. Lupus 1998;7:101–107.
Wolkowitz OM, Weingartner H, Rubinow DR, et al. Steroid modulation of human memory: biochemical correlates. Biol Psychiatry 1993;33:744–746.
Schmidt LA, Fox NA, Goldberg MC, Smith CC, Schulkin J. Effects of acute prednisone administration on memory, attention, and emotion in healthy human adults. Psychoneuroendocrinology 1999;24:461–483.
Richards M, Meade TW, Peart S, Brennan PJ, Mann AH. Is there any evidence for a protective effect of antithrombotic medication on cognitive function in men at risk of cardiovascular disease? Some preliminary findings. J Neurol Neurosurg Psychiatry 1997;62:269–272.
Van Kooten F, Ciagattoni G, Koudstaal PJ, Grobbee DE, Kluft C, Patrono C. Increased thromboxane biosynthesis is associated with poststroke dementia. Stroke 1999;30:1542–1547.
Sturmer T, Glynn RJ, Field TS, Taylor JO, Hennekens CH. Aspirin use and cognitive function in the elderly. Am J Epidemiol 1996;143:683–691.
Hanlon JT, Schmader KE, Landerman LR, et al. Relation of prescription nonsteroidal antiinflammatory drug use to cognitive function among community-dwelling elderly. Ann Epidemiol 1997;7:87–94.

Information & Authors


Published In

Volume 64Number 2January 25, 2005
Pages: 297-303
PubMed: 15668428

Publication History

Published online: January 24, 2005
Published in print: January 25, 2005


Request permissions for this article.


Affiliations & Disclosures

E. Y. McLaurin, BS
From the Department of Medicine, Division of Neurology, San Antonio, TX.
S. L. Holliday, PhD
From the Department of Medicine, Division of Neurology, San Antonio, TX.
P. Williams
From the Department of Medicine, Division of Neurology, San Antonio, TX.
R. L. Brey, MD
From the Department of Medicine, Division of Neurology, San Antonio, TX.


Address correspondence and reprint requests to Dr. Robin L. Brey, Department of Medicine, Division of Neurology, 7703 Floyd Curl Drive #7883, San Antonio, TX 78229-3900; e-mail: [email protected]

Metrics & Citations



Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Causal associations between common musculoskeletal disorders and dementia: a Mendelian randomization study, Frontiers in Aging Neuroscience, 15, (2023).
  2. Cognitive dysfunction in patients with childhood-onset systemic lupus erythematosus may impact treatment, Advances in Rheumatology, 63, 1, (2023).
  3. Prevalence of cognitive impairment and cognitive improvement in patients with systemic lupus erythematosus during a 6-month follow-up study, Lupus, 32, 10, (1199-1210), (2023).
  4. Clinical associations of cognitive dysfunction in systemic lupus erythematosus, Lupus Science & Medicine, 10, 1, (e000835), (2023).
  5. Cognitive dysfunction in pediatric systemic lupus erythematosus: current knowledge and future directions, Child Neuropsychology, (1-29), (2023).
  6. Patterns and prevalence of cognitive dysfunction in systemic lupus erythematosus, Journal of the International Neuropsychological Society, 29, 5, (421-430), (2023).
  7. The effects of synthetic glucocorticoid treatment for inflammatory disease on brain structure, function, and dementia outcomes: A systematic review, Brain Research, 1798, (148157), (2023).
  8. Cognitive Impairment in Anti-Phospholipid Syndrome and Anti-Phospholipid Antibody Carriers, Brain Sciences, 12, 2, (222), (2022).
  9. Increasing of Blood Brain Barrier Permeability and the Association With Depression and Anxiety in Systemic Lupus Erythematosus Patients, Frontiers in Medicine, 9, (2022).
  10. Causal association between systemic lupus erythematosus and the risk of dementia: A Mendelian randomization study, Frontiers in Immunology, 13, (2022).
  11. See more

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Full Text HTML

View Full Text HTML







Share article link